Botanical Drug Sponsors Would Benefit From Simpler Indications – FDAer
This article was originally published in The Tan Sheet
Executive Summary
Sponsoring botanical drug products with indications for less complex diseases - especially those that are currently without effective treatment - could speed up FDA's review of new botanical drugs, according to Shaw Chen, MD, PhD, Associate Director of CDER's Office of Drug Evaluation I